Post-Brexit UK Could Be ‘Back Of The Queue’ For Drug Access, Warns MHRA Chair
Executive Summary
Professor Sir Michael Rawlins, chair of the MHRA, has told a UK committee of his concerns over Brexit, including possible delays in access to new drugs, a decline in revenues for regulatory work on behalf of the EU, and the possibility that some firms’ HQs might follow the European Medicines Agency if it relocates to another European country.
You may also be interested in...
Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health
Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.
UK Industry Pleased With Brexit Committee's Focus On Regulation
Industry group ABPI is focusing on the fact that the report from parliamentarians on the cross-party Exiting the EU Committee has made at least some mention of the need to ensure that medicines regulation is ready for Brexit on “day one.”
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.